-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

A Rational Approach to Functional High-Risk Myeloma

Program: Education Program
Session: How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Clinical Research, Minimal Residual Disease
Sunday, December 10, 2023, 9:30 AM-10:45 AM

Francesca Gay, MD, PhD

Division of Hematology 1, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy

Disclosures: Gay: GlaxoSmithKline: Honoraria, Other: Advisory board; AbbVie: Honoraria, Other: Advisory board; Oncopeptides: Other: Advisory board; Bristol Myers Squibb/Celgene: Honoraria, Other: Advisory board; Roche: Other: Advisory board; Sanofi: Honoraria, Other: Advisory board; Pfizer: Honoraria, Other: Advisory board; Takeda: Honoraria, Other: Advisory board; Janssen: Honoraria, Other: Advisory board; Amgen: Honoraria, Other: Advisory board.

OffLabel Disclosure:

See more of: How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?
See more of: Education Program
Previous Presentation | Next Presentation >>